Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

OBJECTIVE The value of repeated ANCA measurements among patients with an established diagnosis of ANCA-associated vasculitis (AAV) remains controversial. The aim of this study was to explore whether either of the two distinct patterns of ANCA values during remission, a rise in ANCA or persistently positive ANCA, predicted future relapse. METHODS MEDLINE and EMBASE searches were performed. Studies with at least 10 subjects with AAV from which both sensitivity and specificity of a rise in ANCA and/or persistent ANCA for future disease relapse could be calculated were included. Likelihood ratios were calculated for each study and pooled to arrive at summary estimates. I(2)-values were calculated as a measure of heterogeneity and meta-regression was used to explore sources of heterogeneity. RESULTS Nine articles on a rise in ANCA and nine articles on persistent ANCA were included. The summary estimates for positive likelihood ratio (LR(+)) and negative likelihood ratio (LR(-)) of a rise in ANCA during remission on subsequent relapse of disease were 2.84 (95% CI 1.65, 4.90) and 0.49 (95% CI 0.27, 0.87), respectively. The summary estimates for LR(+) and LR(-) of persistent ANCA during remission for subsequent disease relapse were 1.97 (95% CI 1.43, 2.70) and 0.73 (95% CI 0.50, 1.06), respectively. There was substantial between-study heterogeneity, which was partially explained by the frequency of ANCA measurements. CONCLUSION Among patients with AAV, a rise in or persistence of ANCA during remission is only modestly predictive of future disease relapse. There is limited use to serial ANCA measurements during disease remission to guide treatment decisions for individual patients with AAV.

[1]  G. Sebastiani,et al.  [Antineutrophil cytoplasmic antibodies]. , 2011, Reumatismo.

[2]  Patrick M M Bossuyt,et al.  Differences between univariate and bivariate models for summarizing diagnostic accuracy may not be large. , 2009, Journal of clinical epidemiology.

[3]  J. Savige,et al.  Antineutrophil cytoplasmic antibody (ANCA) testing of routine sera varies in different laboratories but concordance is greater for cytoplasmic fluorescence (C-ANCA) and myeloperoxidase specificity (MPO-ANCA). , 2009, Journal of immunological methods.

[4]  J. Piette,et al.  Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides , 2008, Annals of the rheumatic diseases.

[5]  P. van Paassen,et al.  A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis , 2008, Annals of the rheumatic diseases.

[6]  Patrick M Bossuyt,et al.  We should not pool diagnostic likelihood ratios in systematic reviews , 2008, Statistics in medicine.

[7]  Gerta Rücker,et al.  Arcsine test for publication bias in meta‐analyses with binary outcomes , 2008, Statistics in medicine.

[8]  D. Schroeder,et al.  Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis , 2007, Annals of Internal Medicine.

[9]  Augustine S. Lee,et al.  ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. , 2007, The American journal of medicine.

[10]  C. Kallenberg,et al.  Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. , 2006, Rheumatology.

[11]  F. Spertini,et al.  Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis. , 2005, The Journal of rheumatology.

[12]  Johannes B Reitsma,et al.  Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. , 2005, Journal of clinical epidemiology.

[13]  Petra Macaskill,et al.  Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. , 2004, Journal of clinical epidemiology.

[14]  C. Stegeman,et al.  Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. , 2004, Arthritis and rheumatism.

[15]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[16]  U. Specks,et al.  Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. , 2003, The American journal of medicine.

[17]  R. Falk,et al.  Monitoring Proteinase 3 Antineutrophil Cytoplasmic Antibodies for Detection of Relapses in Small Vessel Vasculitis , 2003, Clinical Diagnostic Laboratory Immunology.

[18]  J. Dempster,et al.  Wegener's granulomatosis: an analysis of 33 patients seen over a 10-year period. , 2003, Clinical otolaryngology and allied sciences.

[19]  C. Kallenberg,et al.  Image analysis: a novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener's granulomatosis. , 2003, Journal of immunological methods.

[20]  Hyon K. Choi,et al.  Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. , 2003, Kidney international.

[21]  P. Heeringa,et al.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. , 2002, The Journal of clinical investigation.

[22]  J. Wieslander,et al.  Relationship between anti‐neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long‐term clinical course in vasculitis , 2002, Journal of internal medicine.

[23]  J. Font,et al.  Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of antineutrophil cytoplasmic antibodies (ANCA) in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients. , 2001, Clinical nephrology.

[24]  G. Riet,et al.  Systematic reviews of evaluations of diagnostic and screening tests , 2001, BMJ : British Medical Journal.

[25]  F. J. van der Woude,et al.  ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  Jonathan J Deeks,et al.  Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. , 2001, BMJ.

[27]  G A Colditz,et al.  Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. , 2001, The Journal of rheumatology.

[28]  R. Solans,et al.  Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. , 2001, Rheumatology.

[29]  M. André,et al.  Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. , 2001, Rheumatology.

[30]  E. Mirapeix,et al.  Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  E. Hachulla,et al.  Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. , 1999, The American journal of medicine.

[32]  J. Ara,et al.  Valor de los anticuerpos anticitoplasma del neutrófilo, antiproteinasa 3 y antimieloperoxidasa en el seguimiento de las vasculitis de pequeño vaso , 1998 .

[33]  P Lesavre,et al.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. , 1998, Kidney international.

[34]  K. De Groot,et al.  Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). , 1997, Journal of immunological methods.

[35]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[36]  S. Sharp,et al.  Explaining heterogeneity in meta-analysis: a comparison of methods. , 1997, Statistics in medicine.

[37]  P. Merkel,et al.  Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease , 1997, Annals of Internal Medicine.

[38]  A. Dash,et al.  Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  L. Noel,et al.  Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. , 1995, Clinical and experimental rheumatology.

[40]  C. Pusey,et al.  ANCA and predicting relapse in systemic vasculitis. , 1995, QJM : monthly journal of the Association of Physicians.

[41]  D. Adu,et al.  Relapses in patients with a systemic vasculitis. , 1993, The Quarterly journal of medicine.

[42]  T. Chan,et al.  Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  C. Hallahan,et al.  Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. , 1993, Arthritis and rheumatism.

[44]  E. Pettersson,et al.  Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. , 1992, Clinical nephrology.

[45]  A. Weetman,et al.  IgG subclass distribution and relative functional affinity of anti-myeloperoxidase antibodies in systemic vasculitis at presentation and during follow-up. , 1991, Immunology.

[46]  H. Chapel,et al.  Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides , 1990, Clinical and experimental immunology.

[47]  T. The,et al.  Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre , 1990, The Lancet.

[48]  C. Kallenberg,et al.  Association between active Wegener's granulomatosis and anticytoplasmic antibodies. , 1989, Archives of internal medicine.

[49]  U. Specks,et al.  Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. , 1989, Annals of internal medicine.

[50]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.

[51]  WS Rutjes.  The Development of QUADAS:A Tool for the Quality Assessment of Studies of Diagnostic Accuracy Included in Systematic Reviews , 2007 .

[52]  E. Mirapeix,et al.  [Usefulness of anti-neutrophil cytoplasmic antibodies, anti-proteinase 3 and anti-myeloperoxidase in management of small vessel vasculitis]. , 1998, Medicina clinica.

[53]  A. Davenport,et al.  Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. , 1995, American journal of nephrology.

[54]  C. Kallenberg,et al.  Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis , 1994, Annals of Internal Medicine.

[55]  E. Hachulla,et al.  Sensibilité et spécificité des anticorps anticytoplasme des neutrophiles (c-ANCA) au cours des vascularites systémiques , 1994 .

[56]  A. Dash,et al.  Relationship between disease activity and ANCA level by ELISA in the long-term management of vasculitis. , 1993, Advances in experimental medicine and biology.

[57]  J. Subra,et al.  Place du titrage des anticorps anticytoplasme des polynucléaires neutrophiles dans le suivi thérapeutique des patients atteints de vascularite systémique , 1993 .

[58]  C. Masson,et al.  [Role of the titration of anti-neutrophil cytoplasmic antibodies in therapeutic follow-up of patients with systemic vasculitis]. , 1993, La Revue de medecine interne.

[59]  G. Samsa,et al.  Likelihood ratios with confidence: sample size estimation for diagnostic test studies. , 1991, Journal of clinical epidemiology.

[60]  C. Pusey,et al.  Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[61]  M. Daha,et al.  Value of anti-neutrophil cytoplasmic autoantibodies and other laboratory parameters in follow-up of vasculitis. , 1990, Scandinavian journal of rheumatology.

[62]  C. Wheatley,et al.  Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. , 1989, Mayo Clinic proceedings.